Skip to content

Supporting Informed Decision Making About Multi-cancer Early Detection Testing

Supporting Informed Decision Making About Multi-cancer Early Detection Testing

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06870916
Enrollment
150
Registered
2025-03-11
Start date
2025-03-07
Completion date
2027-01-01
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multi-cancer Early Detection

Brief summary

To develop a new participant educational aid that can be used by participants to support informed decision-making about Multi-Cancer Early Detection (MCED) tests, which are new blood-based screening tests.

Detailed description

To develop a prototype participant educational aid that can be used by participants to support informed decision making about MCED testing. The aims of the pilot project include the following: 1. Conduct focus groups to explore preferences and concerns about MCED testing among adults of screening age. 2. Based on salient themes from focus group discussion, develop and administer surveys to explore preferences and concerns about MCED testing among adults of screening age. 3. Using findings from the focus groups and surveys, develop prototype patient educational aids about MCED testing following a user-centered design strategy.

Interventions

Participants will participate in a focus group discussion asking about your knowledge, preferences, and concerns for MCEDs. During the focus group discussion, investigators will specifically talk about what the tests are and how to decide to get the test as well as their risks and benefits.

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Recruitment and eligibility will be assessed by CCETR.CCETR staff will help distribute recruitment flyers, assess subject eligibility, and refer eligible subjects to the research team (Appendix B, C \& I).

Exclusion criteria

• History of cancer other than basil cell and squamous cell skin cancer, per self-report.

Design outcomes

Primary

MeasureTime frame
Safety and Adverse Events (AEs)Through study completion; an average of 1 year.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRobert Volk, PHD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026